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Abstract: Background: Diagnosing cardiac amyloidosis (CA) from cine-CMR (cardiac magnetic
resonance) alone is not reliable. In this study, we tested if a convolutional neural network (CNN)
could outperform the visual diagnosis of experienced operators. Method: 119 patients with cardiac
amyloidosis and 122 patients with left ventricular hypertrophy (LVH) of other origins were retrospectively selected. Diastolic and systolic cine-CMR images were preprocessed and labeled. A dual-input
visual geometry group (VGG ) model was used for binary image classification. All images belonging
to the same patient were distributed in the same set. Accuracy and area under the curve (AUC)
were calculated per frame and per patient from a 40% held-out test set. Results were compared to a
visual analysis assessed by three experienced operators. Results: frame-based comparisons between
humans and a CNN provided an accuracy of 0.605 vs. 0.746 (p < 0.0008) and an AUC of 0.630 vs.
0.824 (p < 0.0001). Patient-based comparisons provided an accuracy of 0.660 vs. 0.825 (p < 0.008) and
an AUC of 0.727 vs. 0.895 (p < 0.002). Conclusion: based on cine-CMR images alone, a CNN is able to
discriminate cardiac amyloidosis from LVH of other origins better than experienced human operators
(15 to 20 points more in absolute value for accuracy and AUC), demonstrating a unique capability to
identify what the eyes cannot see through classical radiological analysis.
Keywords: cardiac amyloidosis; AL/TTR amyloidosis; hypertrophic cardiomyopathy; left ventricular
hypertrophy; deep learning; convolutional neural network
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1. Introduction

iations.

Cardiac amyloidosis (CA) is a specific cardiomyopathy caused by the deposition of
misfolded amyloid fibrils in the extracellular myocardial space. Light-chain (AL) and
transthyretin (TTR) are the most common subtypes. Cardiac amyloidosis is a fatal disease
requiring rapid diagnosis for patients to benefit from recently released medications [1–3].
Its diagnosis has gained significant improvements in recent years, in particular with the
recognition of diphosphonate SPECT imaging for the identification of the TTR form of the
disease [4].
MRI plays an important role in this field thanks to gadolinium injections providing
quite a specific pattern of myocardial late-enhancement [5] and demonstrating highly
relevant extracellular volume (ECV) increase [6]. Despite recent relief in the restrictions
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on the use of gadolinium chelates [7], caution needs to be exercised in case of renal impairment, and a diagnostic approach without injection would be beneficial. Steady-state
free precession (SSFP) cine-CMR is a basic method in cardiac MRI, offering a good quality
morphological and functional depiction of important cardiac features [8]. Myocardial wall
thickening, atrial enlargement and pericardial or pleural effusion constitute the hallmarks
of amyloid cardiac involvement [9]. However, these signs are very nonspecific since they
are also seen in many other etiologies of left ventricular hypertrophy such as advanced
hypertensive disease, aortic stenosis and other overload diseases such as Fabry disease and
sarcomeric hypertrophic cardiomyopathies, which is why cine-CMR alone is not recognized
as effective for diagnosing cardiac amyloidosis.
Machine learning and, particularly, deep learning applied to imaging quickly established themselves in most pathological areas, and these methods are now recognized as
having diagnostic capacities similar to experienced radiologists, particularly in cardiomyopathies [10] and cardiac amyloidosis [11]. An even more interesting fact concerns the
superior diagnostic capacities of deep learning over human readers in some fields, such
as breast cancer [12], especially its ability to identify pathologies invisible to the naked
eye, such as abnormalities discernible only in immunohistochemistry or through genetic
analysis. For example, deep learning was reported to be efficient in improving mutation
prediction in hypertrophic cardiomyopathy using MR-cine images [13].
This innovative concept led us to initiate the present study in which we compared the
performance of commonly available deep learning methods to experienced radiologists to
discriminate cardiac amyloidosis from other myocardial hypertrophies based on cine-CMR
alone. Moreover, we explored the capacity of deep learning to differentiate AL from TTR
amyloidosis, which is not reliably achievable visually with cine-CMR.
2. Materials and Methods
2.1. Study Population
We retrospectively analyzed the cine-CMR sequences of patients performed between
2010 and 2020 in the radiology department of our hospital. This study was registered and
approved by the Institutional Review Board of our university hospital, and all datasets
were obtained and de-identified, with waived consent in compliance with the rules of our
institution. The cine-CMR exams of 241 patients were studied, including 119 with histologically proven amyloidosis and 122 with left ventricular hypertrophy without amyloidosis
(LVH). The patients’ characteristics are listed in Table 1.
The left ventricular hypertrophy without amyloidosis group (n = 122) consisted of
patients referred to CMR for suspected cardiac amyloidosis due to several suggestive
features such as a heart failure episode, thickening of the myocardial walls on ultrasound
examination, restrictive transmitral Doppler filling pattern, reduced longitudinal strain with
apical sparring, monoclonal gammopathy or dubious Perugini grade 1 bone scintigraphy.
Other cases presented a CMR of concentric left ventricular hypertrophy (left ventricular wall
thickness ≥13 mm in diastole). The clinical context was consistent with hypertension, aortic
stenosis or non-obstructive hypertrophic cardiomyopathy. Late-enhancement imaging
obtained in all cases never demonstrated circumferential subendocardial or diffuse lateenhancement patterns suggestive of amyloid involvement.
For the amyloidosis group (n = 119), the selection criteria for amyloidosis diagnosis
were based on typical CMR features confirmed by clinical, biological, bone scintigraphic
and anatomo-histological findings. Left ventricular wall thickening (≥13 mm in diastole), left ± right atrial dilatation, increased native myocardial T1 relaxation time and/or
extracellular volume (ECV), pericardial or pleural effusion and typical subendocardial
late-enhancement pattern (circumferential, diffuse or not related to a coronary territory)
were the main diagnostic clues for amyloidosis.
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Table 1. Clinical and CMR characteristics of the study population.
Amyloidosis

LVH

N patients

119

122

Age (years)

74.65 ± 9.53

59.50 ± 14.34

p

0.0001

Sex (F/M)

31/88

39/83

0.31

Weight (kg)

70.80 ± 15.16

82.95 ± 20.50

0.0001

Height (m)

169.9 ± 8.84

170.36 ± 10.05

0.78

BSA (m2 )

1.84 ± 0.22

2.00 ± 0.27

<0.0001

IVS (mm)

18.11 ± 3.54

18.38 ± 3.54

0.56

LVMI (g/m2 )

115.96 ± 29.08

116.58 ± 31.43

0.88

LVDVI (mL/m2 )

69.88 ± 22.21

74.51 ± 20.82

0.36

LVEF (%)

58.96 ± 10.93

67.33 ± 12.18

<0.0001

LA surface (cm2 )

31.55 ± 5.23

25.47 ± 5.96

0.0002

Systolic time (ms)

321 ± 39

332 ± 40

0.095

T1 (ms)

1138.5 ± 48.1

1038.0 ± 56.2

<0.0001

ECV (%)

53.97 ± 11.17

26.89 ± 4.00

<0.0001

N long axis frames/patient

2.24 ± 0.93

2.22 ± 0.94

0.93

N short axis frames/patient

3.41 ± 1.45

3.59 ± 1.27

0.49

N frames/patient

5.68 ± 1.85

5.47 ± 1.81

0.58

N frame post-gadolinium

171/676

167/667

0.96

N patient with pericard.

54 (45%)

27 (22%)

0.00013

N patients with pleural.

45 (38%)

10 (8%)

0.00001

N patients with both.

24 (20%)

3 (2.5%)

0.00001

The characteristics of patients with amyloidosis and left ventricular hypertrophy were included in this study. The
number of observations, (integer) or average values ± standard deviation, are listed: BSA: body surface area; IVS:
interventricular septum thickness; LVMI: left ventricular mass index; LVDVI: left ventricular diastolic volume
index; LVEF: left ventricular ejection fraction; LA: left atrial; systolic time: the time of the systolic image; and ECV:
extracellular volume. Between the parentheses is the percentage. Pericard. is for pericardial effusion, pleural is for
pleural effusion and both is for pericardial + pleural effusions.

The characteristics of AL and TTR patients can be found in the supplemental material
(Table S1). TTR amyloidosis was defined in 38 patients without monoclonal gammopathy
and with a 99m Tc-diphosphonate SPECT Perugini score of >1 or with amyloid deposits on
an extracardiac and/or endomyocardial biopsy. AL amyloidosis was reported in 59 cases,
based on the detection of a kappa/lambda free light-chain with monoclonal gammopathy
and an extracardiac and/or endomyocardial biopsy. Among the 22 patients who were
not categorized as AL or TTR, three were AA type, three had uncertain immunostaining,
one had Perugini 1 and no gammopathy, four elderly patients died and 11 were lost to
follow-up.
For the cine-CMR acquisitions, all images were obtained at 1.5 Tesla, using three
Siemens (Erlangen, Germany) and one Philips (Eindhoven, The Netherlands) scanners.
Steady-state free precession (SSFP) cine sequences were obtained with TE/TR 1.6/3.5 ms, 8
to 32 elements cardiac coil and 6 to 8 mm thick slices. End-systole (with the smallest left
ventricular dimension) was visually selected (systolic time in Table 1). Orientation planes
were long axis (4-chamber and vertical 2-chamber views) and short axis views. Table 1 lists
the summary of acquisition parameters.
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2.2. Image Preparation
The image preparation of cine studies exported from the PACS of our hospital was
carried out with a dedicated Visual C software. All images were first de-identified and
resampled (bilinear) in order to obtain a normalized homogeneous pixel size of 1.5 mm.
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2.3. Deep Learning Process
2.3. Deep Learning Process
CNN implementation was performed in Python 3.7.6, with Keras library and TenCNN implementation was performed in Python 3.7.6, with Keras library and TensorsorFlow backend. According to CLAIM recommendations [14], the data were distributed
Flow backend. According to CLAIM recommendations [14], the data were distributed in
in order to ensure that images of the same patient always lie in either the train set, the
order to ensure that images of the same patient always lie in either the train set, the valivalidation set or the test set (no mixture between these sets).
dation set or the test set (no mixture between these sets).
For hyperparameter trimming, data processing was performed according to the diaFor hyperparameter trimming, data processing was performed according to the diagram shown in Figure 2. A 40% test set (538 pairs of frames and 96 patients) was isolated
gram shown in Figure 2. A 40% test set (538 pairs of frames and 96 patients) was isolated
and stored as a held-out test set. With the 60% remaining data, a three-fold cross-validation
and stored
a held-outintest
set.to
With
60% remaining(batch
data, asize,
three-fold
cross-validatraining
wasasperformed
order
trimthe
hyperparameters
optimizer,
learning
tion
training
was
performed
in
order
to
trim
hyperparameters
(batch
size,
optimizer,
rate, decay, number of trainable layers, dropout rate and parameters of the image
data
learning rate,
decay,
trainable
layers, dropout
rate and training
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the image
generator).
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wasnumber
done toofavoid
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of individual
andofvalidation
data generator).
was
to avoid the influence of individual training and validation
examples
on the This
choice
of done
hyperparameters.
examples on the choice of hyperparameters.
With optimal hyperparameters, a final model was built with all training data and
evaluated on the test set. Patient-based metrics were calculated from the average of the
predicted probability corresponding to all frames of a unique patient.
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3. Results
3.1. Amyloidosis vs. LVH Classification Obtained with the Held-Out Test Set According to the
Input Shape
Table 2 lists the results obtained with the various input shapes illustrated in Figure 1.
Patient-based results were always better than frame-based results.
Table 2. Accuracy and AUC of the ROC curve for classification of amyloidosis vs. LVH in the 40%
held-out test group, according to the input shape.
Frame-Based

Patient-Based

Input Shape

Accuracy

ROC AUC

Accuracy

ROC AUC

160 × 160/D + S

0.759

0.836
[0.786–0.878]

0.812

0.937
[0.828–0.987]

160 × 160/D

0.760 (ns)

0.820 (ns)
[0.769–0.864]

0.833 (ns)

0.918 (ns)
[0.802–0.978]

160 × 160/S

0.733 (ns)

0.801 (0.04)
[0.749–0.848]

0.833 (ns)

0.890 (ns)
[0.767–0.962]

256 × 256/D + S

0.710 (ns)

0.790 (0.03)
[0.735–0.836]

0.771 (ns)

0.803 (0.02)
[0.663–0.904]

224 × 224/D + S

0.728 (ns)

0.823 (ns)
[0.772–0.867]

0.812 (ns)

0.852 (ns)
[0.720–0.938]

128 × 128/D + S

0.740 (ns)

0.808 (ns)
[0.756–0.853]

0.812 (ns)

0.922 (ns)
[0.807–0.979]

Epicardial ROI

0.722 (ns)

0.787 (0.01)
[0.762–0.810]

0.791 (ns)

0.888 (ns)
[0.839–0.927]

Myocard. ROI

0.662 (0.05)

0.719 (0.01)
[0.693–0.745]

0.714 (ns)

0.814 (0.03)
[0.756–0.863]

Results obtained with the 40% held-out test set after hyperparameters tuning. 160 × 160 indicates the cropping
size of input frames. D and S indicate diastole and systole. Between brackets is the confidence interval of AUC.
Values between parentheses indicate the level of significance of the difference as compared to the 160 × 160 D + S
result (assessed with Chi-square test from the number of observations for accuracy and assessed by Delong test
for AUC comparisons).

Optimal performance was obtained with 160 × 160 cropped diastolic and systolic
images in which per frame analysis provided a test accuracy of 0.759 and an AUC of 0.836,
whereas per patient analysis provided a test accuracy of 0.812 and an AUC of 0.937.
Combining diastole and systole did not improve the results. Full field 256 × 256
frames and focused myocardial ROI images provided significantly weaker results.
3.2. Amyloidosis vs. LVH Classification Obtained with the Held-Out Test Set by Human Readers
and by CNN
The comparison between classification by experienced radiologists/cardiologists and
the CNN is given in Table 3. The CNN provided a largely superior performance when
compared to human readers.
Frame-based comparisons of human vs. CNN classification led to an accuracy of 0.605
vs. 0.746 (p < 0.0008) and an AUC of 0.630 vs. 0.824 (p < 0.0001).
Patient-based comparisons provided an accuracy of 0.660 vs. 0.825 (0.008) and an AUC
of 0.727 vs. 0.895 (p < 0.002). The ROC curves of these comparisons are plotted in Figure 3.
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Table 3. Accuracy and AUC of the ROC curve for classification of amyloidosis vs. LVH in the held-out
test group for human readers vs. CNN.

Metric
Metric
CNN

Read 1

Accur.
CNN
0.746

Read 1

(0.001)

0.623
(0.005)

69.6
54.5
0.585

0.585
(0.001)
Read

66.4
50.9
0.605

(avg)
Read
(avg)

77.0
0.585
71.0
66.4
50.85
0.623

Read 3

Read 3

Sensitiv.
0.746
Specific.

0.585
(0.001)

Read 2

Read 2

Sensitiv.

Accur.
Frame-Based
Specific.

(0.005)

(0.001)

(0.0008)

ROC AUC

77.0
71.0

0.824
Accur.
[0.770–0.869]
0.570
0.824
0.825
66.4
[0.770–0.869] [0.506–0.632]
50.85
(0.0001)
0.570
0.629
[0.506–0.632]
0.623
(0.004)
69.6
(0.0001) [0.560–0.684]
54.5
(0.0001)
0.623
0.649
[0.560–0.684]
0.587
(0.009)
66.4
(0.0001) [0.523–0.649]
50.9
0.587
(0.0001)
0.660
[0.523–0.649]
0.630
(0.013)
69.2
(0.0001)
[0.567–0.690]
52.7
0.630
(0.0001)
0.660
ROC AUC

Sensitiv.
Accur.
ROC AUC
Patient-Based
Specific.
Sensitiv.
85.7
0.895
ROC AUC
0.825
Specific.
77.6
[0.816–0.948]
0.654
85.7
0.895
0.629
67.4
77.6
[0.816–0.948]
[0.550–0.747]
(0.004)
58.8
(0.001)
0.654
67.4
[0.550–0.747] 0.712
58.8
0.649
69.6(0.001)
[0.611–0.799]
(0.009)
60.8
(0.0002)
0.712
69.6
[0.611–0.799] 0.731
60.8
0.660
71.1
(0.0002) [0.631–0.816]
(0.013)
61.5
0.731
(0.002)
71.1
[0.631–0.816] 0.727
61.5
0.660
72.1(0.002)
[0.627–0.813]
(0.008)
61.1
0.727
(0.002)
72.1

0.605
69.2
[0.567–0.690]
[0.627–0.813]
Frame-based52.7
and patient-based
results obtained
with the held-out
test set
by human readers and
(0.0008)
(0.008)
61.1
(0.0001)
(0.002)
by CNN. Accur. is for accuracy, Sensitiv. and Specific. are for sensitivity and
specificity. Values
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4.2. Superiority of CNN Capacities over Human Diagnosis
The aim of this study was not to propose making the diagnosis of cardiac amyloidosis
solely on the cine-CMR data because much more relevant CMR indices are available thanks
to gadolinium injection. Actually, late-enhancement and ECV allow the diagnosis of the
presence of CA with a high sensitivity of 95% and an even higher specificity of 98% [5], and
deep learning was demonstrated to be efficient in this field [11]. Our goal was to show that
deep learning is able to extract diagnostic clues clearly surpassing visual analysis (15 to
20 points in the present study).
Excellent performances of the CNN are often reported in the literature, but their
interest is limited if they are not compared to human performance. Among human–machine
comparisons, many studies have reported that CNN diagnosis is on par with human
visual assessment in multiple areas [17]. For example, for malignancy risk estimation of
pulmonary nodules using thoracic CT, Venkadesh et al. [18] reported that the DL algorithm
had an AUC of 0.96, which was significantly better than the average AUC of the clinicians
(0.90) but comparable to that of thoracic radiologists. Our model was able to discriminate
between AL and TTR CA with interesting values of patient-based accuracy (0.711) and
AUC (0.752); however, this was no better than the classification obtained with the simple
measurement of the septal thickness, already reported in previous publications [19–21] and
resulting from the known increased amyloid burden in this subtype.
Of more interest is to show significant machine-over-human superiority in routine
areas, where “clinical” visual analysis is the classic benchmark. Our study provides
an interesting demonstration in this direction for diagnosing cardiac amyloidosis from
cine-CMR. A small number of other publications could demonstrate that AI systems
are capable of surpassing human experts in disease prediction. Such is the case for the
distinction between low-grade and high-grade glioma by radiologists, which lacks accuracy
(40–45% of non-enhancing MR lesions are found subsequently to be malignant glioma),
whereas, in contrast, CNN-based grading provides > 90% accuracy [22]. Resnet-50 CNN
outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image
classification task [23]. For the diagnosis of breast cancer, in a large multicenter study, Mc
Kinney et al. [12] found that the AI system exhibited specificity and sensitivity superior
to that of radiologists practicing in an academic medical center and exceeded the average
performance of radiologists by a significant improvement in the area under the ROC curve
(∆AUC = +0.115). Similarly, in differentiating benign from malignant renal tumors, Xu
et al. [24] reported higher AUC with the CNN model (0.906, based on T2-weighted images)
as compared to the AUC obtained by two radiologists (0.724).
4.3. Unveiling the Invisible
One more step in this diagnostic quest is the possibility of discriminating pathological
conditions that clinicians are not able to predict at all using the naked eye. Subtyping
molecular markers, histological or immune-histochemical and genetic classes is impossible
to ascertain from radiologic data. These identifications were initially proposed from
radiomic signatures, for instance, to discriminate between hypertensive heart disease and
hypertrophic cardiomyopathy [25] or between recent infarction vs. old infarction [26].
However, several comparative studies have demonstrated that deep learning based on
radiologic data is superior to radiomics. This has been demonstrated for renal cancer [24],
subtyping different types of cerebral glioma [27], diagnosis of breast cancer [28] and
predicting axillary lymph node metastasis of breast cancer [29].
This may be explained because radiomics’ features are handcrafted in advance and,
thus, may not always fit to discriminate particular tasks. In contrast, the CNN is more
flexible, adaptive and dynamic. As a data-driven tool, it is able to automatically learn
to extract and select task-specific features if the amount of training data is large enough.
Further evidence for the power of deep learning to make a histological diagnosis from
radiological data has been provided by Zhao et al. for renal cell carcinomas Fuhrmangrading [30] and by Yuan et al. for prostate cancer Gleason score staging (accuracy 0.87) [31].
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4.4. Explanation of Classification Remains Unsatisfactory
Deep neural networks operate through a multilayer nonlinear structure, making
their predictions difficult to interpret. They are able to pick up a number of features
that cannot be interpreted by humans but which are relevant for making a diagnosis.
These automatically-learned discriminative features are unfortunately presently not clearly
identifiable.
Grad-CAM helps identify the areas of pixels that are most responsible for class prediction [16]. This should provide valuable clues to understand the algorithm’s decision. In
principle, the salient areas should be located in the cardiac region, which only appeared in
a quarter of the cases in our study. Two explanations may be advanced for this anomaly.
(1) Technically, our network uses only fully connected layers in the last phase, which
is where the classification happens, but saliency cannot be obtained from fully connected
layers. As a solution, we should try replacing some of the fully connected layers that come
right after VGG with convolution. This way, the spatial information would be preserved
longer in the network, and we might see more meaning in the saliency maps.
(2) Amyloidosis is not a disease confined to the heart since the involvement of the
lungs, fatty tissues and other organs is also common. Liver and, moreover, spleen amyloid
deposits have been reported in 41% of patients with systemic amyloidosis (almost only
in AL type), and CMR-derived ECV measurement showed good diagnostic capability in
this field [32]. This is why the diagnosis is also based on extracardiac biopsies, and it is
interesting to note that the texture analysis was able to show specificities in the architecture
of ultrasound images within abdominal fat [33], resulting in increased echogenicity and
a loss of the normal structure of the fat layer, consistent with histopathological amyloid
deposition in the fat.
This ubiquitous aspect of the disease may also explain why the input shape submitted
to the CNN (from the full field image to the small region of interest focused on the sole
myocardium illustrated in Figure 1) hardly modifies the performance of our model as
shown in Table 2. It can also be noted in Table 2 that the combination of diastole and systole
does not provide any diagnostic benefit, unlike for other cardiomyopathies [10], because
the global LV systolic function is generally preserved in the early stage of amyloidosis.
4.5. Study Limitations
Two types of confounding factors must be mentioned. First, plane orientation and the
presence of gadolinium in the sets of images could have influenced the results, but Table 1
shows a perfect equivalence between the two groups. Second, the presence of pericardial or
pleural effusion constitutes a more important bias because the prevalence (slightly higher
than in the study of Binder et al. [9]) is very different in the two groups. Pericardial effusion
is observed in almost 50% of CA, i.e., two times more often than in hypertrophies unrelated
to amyloidosis. Pleural effusions are observed in just over a third of CA, i.e., four times
more than in other hypertrophies, and mixed effusions are 10 times more frequent in the
amyloidosis group than in the LVH group. This disparity probably contributes to the
classification made by CNNs (although heat maps rarely focus on areas of effusion) but
also influences clinical judgment, so that the bias is the same for the machine and for the
human, which, therefore, does not explain the diagnostic superiority of the algorithm.
A multiparametric approach is needed. Only cine-CMR data has been used here, and
it is likely that one could significantly improve performances by combining the analysis
with other CMR sequences such as T1 mapping, ECV assessment and late gadoliniumenhancement imaging. Based on gadolinium-enhanced images—and not on cine-MR
images—Martini et al. obtained an accuracy of 0.88 and AUC of 0.98 [11], but remember
that our aim was not to develop the best model to optimize cardiac amyloidosis diagnosis
but to compare CNN and human reader performance. For the distinction between AL and
TTR CA, it has been reported that transmural patterns of late gadolinium enhancement
may differentiate these two types of the disease [21] but with relatively low performance.
Recently, the use of a logistic regression model integrating T2 mapping (slightly increased
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in the AL subtype) and right ventricular ejection fraction combined with age was reported
to discriminate between these two subtypes with an AUC of 0.92 [34]. The performance of
AI integrating such multiparametric CMR features, especially for the distinction between
AL and TTR cardiac amyloidosis, should be explored in the future.
Technical improvements should be implemented. The leverage of more sophisticated CNN models (not limited to the classical VGG model used here) and, moreover, the
combination (concatenation) of several multiparametric inputs, with possible additional
categorical clinical input variables (e.g., [30]), should improve performance. Orientation
plane specific models [11] should also be tested since images of different views were classified here by the same network, which makes learning relevant features from images
potentially much harder as it increases variability unrelated to any disease. Significant
work also remains to be done to improve the explainability of the results. Finally, the relatively limited number of observations and the monocentric nature of this study constitute
another limitation. Multicenter studies could be of interest for the further validation and
generalization of our findings.
5. Conclusions
In this study, based on cine-CMR images alone, we could demonstrate the ability of
CNNs to discriminate cardiac amyloidosis from LVH of other origins significantly better
than experienced human operators. The diagnostic accuracy and AUC were 15 to 20 points
higher (in absolute value) for the VGG convolutional network used here than for human
readers. This diagnostic superiority of the CNN results from the unique capability of
the algorithm to identify features invisible to the naked eye, indiscernible through the
classical radiological analysis. This scientific novelty, already reported in a few recent
articles concerning other pathological fields, opens up promising prospects for improving
diagnostic capacities in routine clinical practice. The astonishing potential of CNNs to
improve the recognition of pathologies that are imperfectly detectable in radiology and to
reveal invisible clues such as the histological type of lesions will certainly constitute a large
field of future research.
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